HCW Biologics (NASDAQ:HCWB – Get Free Report) and ImmunityBio (NASDAQ:IBRX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Risk and Volatility
HCW Biologics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for HCW Biologics and ImmunityBio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| ImmunityBio | 1 | 0 | 5 | 0 | 2.67 |
Insider & Institutional Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 42.7% of HCW Biologics shares are held by company insiders. Comparatively, 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares HCW Biologics and ImmunityBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -2,849.17% | N/A | -43.48% |
| ImmunityBio | -422.28% | N/A | -98.33% |
Valuation and Earnings
This table compares HCW Biologics and ImmunityBio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HCW Biologics | $2.57 million | 1.31 | -$30.02 million | ($12.06) | -0.10 |
| ImmunityBio | $14.74 million | 136.32 | -$413.56 million | ($0.41) | -4.98 |
HCW Biologics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
ImmunityBio beats HCW Biologics on 8 of the 13 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
